424B3424B3
Jun 18, 2026Final prospectus0001493152-26-029325
All companies
Trade Aim Immunotech Inc
AIM ImmunoTech Inc. (NYSE American: AIM) Raises $2.65 Million in Registered Direct Offering and Concurrent Private Placement
AI
Aim Immunotech Inc
AIMPublicArchived
Public / ArchivedUnited States(NYSE)Best valuation $10.62M1 market
Public listing
Listed· NYSE· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NYSEIPO
AIMPrice
$0.3829
24h
+0.79%
Valuation
$10.62M
24h volume
$540.03K
Type
IPO
Trade Aim Immunotech IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0000946644.
Revenue · -48.24% YoY
$88K
Net income
-$13.96M
Gross margin
—
Cash
$2.99M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $88K | $170K | $202K | $141K | $135K |
| Operating income | -$11.66M | -$19.77M | -$31.92M | -$19.92M | -$18.84M |
| Net income | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M |
| R&D expense | $3.92M | $6.2M | $10.94M | $6.99M | $7.67M |
| Cash & equivalents | $2.99M | $1.7M | $5.44M | $27.05M | $32.09M |
| Total assets | $5.78M | $8.61M | $19.38M | $40.49M | $57.7M |
| Total liabilities | $15.57M | $9.93M | $9.15M | $2.02M | — |
| Shareholders' equity | -$9.78M | -$1.32M | $10.23M | $38.47M | $56.88M |
About Aim Immunotech Inc
AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers, immune disorders, and viral diseases.
What the company does
- Develops Ampligen, an investigational immuno-modulator based on rintatolimod and designed to activate innate immune pathways.
- Explores clinical applications across oncology, chronic immune conditions, viral disease, and other immune-system indications.
- Relies on clinical research, regulatory progress, intellectual property, and manufacturing readiness to advance its pipeline.
Business profile
AIM ImmunoTech belongs to the biotechnology market, where evidence from clinical studies, regulatory pathways, capital needs, and partnering opportunities define long-term potential.
SEC IPO filings
Final prospectusEDGAR filings resolved from AIM / CIK 0000946644.
S-1S-1
Jun 18, 2026Filed0001493152-26-029193
Jun 16, 2026Effective9999999995-26-002022
S-1S-1
Jun 8, 2026Filed0001493152-26-027714
424B3424B3
Feb 27, 2026Final prospectus0001493152-26-008256
424B4424B4
Feb 17, 2026Final prospectus0001493152-26-006944
Feb 10, 2026Effective9999999995-26-000511
S-1/AS-1/A
Feb 10, 2026Amended0001493152-26-005975
S-1/AS-1/A
Jan 29, 2026Amended0001493152-26-004238
S-1/AS-1/A
Jan 23, 2026Amended0001493152-26-003343
S-1S-1
Dec 12, 2025Filed0001493152-25-027319
Jul 28, 2025Effective9999999995-25-002368
Latest Aim Immunotech Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
StreetInsiderJun 9, 2026IPO filing
AIM ImmunoTech entered into definitive agreements for a registered direct offering and concurrent private placement expected to generate approximately $2.65 million in gross proceeds, with closing on or about June 10, 2026. The company will issue 2,554,119 shares at $0.5189 per share and the concurrent placement includes Class J warrants to purchase up to 10,216,476 shares (with a five-year term from the initial exercise date, subject to stockholder approval).
Aim Immunotech Inc IPO — frequently asked questions
- When did Aim Immunotech Inc go public?
- Aim Immunotech Inc has already gone public and now trades publicly on NYSE under the ticker AIM.
- Can I buy Aim Immunotech Inc stock?
- Yes — Aim Immunotech Inc is publicly traded on NYSE as AIM. You can follow its live price, valuation and post-IPO performance above.
- What is Aim Immunotech Inc's valuation?
- Aim Immunotech Inc's most recent valuation tracked here is $10.62M, derived from live market prices.